GRC 27864 First in Man, Single Ascending Dose Study in Healthy Volunteers

Study Overview
=================
Brief Summary
-----------------
A Single Dose Study of GRC 27864 in Healthy Volunteers.

Detailed Description
-----------------
This is a phase I study of GRC 27864 in healthy volunteers. The purposes of this study are to look at safety, how well the study drug is tolerated, how much of the study drug gets into the blood stream, and how long it takes the body to get rid of it when given to humans. Information about any side effects that may occur will also be collected. Participants will remain in the study for approximately 3 months. This study is for research purposes only and is not intended to treat any medical condition.

Official Title
-----------------
A Three-Part, Phase I Study Of Orally Administered GRC 27864, A Novel, Microsomal Prostaglandin E Synthase-1 Enzyme (mPGES-1) Inhibitor, To Evaluate The Safety, Tolerability And PK Of Single Ascending Doses In Healthy, Adult Subjects (Part 1a), And Of A Single Dose In Elderly Subjects (Part 2); The Effect Of Food On PK (Part 1b) In Healthy, Adult Subjects; And To Compare The Effects On Prostanoid Metabolism With Celecoxib (Part 3) In Healthy, Adult Subjects.

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Drug: GRC 27864
* Drug: Celecoxib
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male or female healthy subjects, age ≥18 to ≤55 years (≥65 years for elderly subjects study) at the time of informed consent Body mass index between 18.5 and 32.0 kilograms per square meter (kg/m2), inclusive Female subjects who are of child-bearing potential or had tubal ligation must agree to use highly effective methods of contraception Male subjects whose partners are of child-bearing potential or had tubal ligation must also agree to use two highly effective method of contraception Exclusion Criteria: Subjects with inherited or acquired disorders in platelet function, bleeding or coagulation. Presence of any clinically relevant acute or chronic disease which could interfere with the subject safety during the clinical study, expose the subject to undue risk. Veins unsuitable for repeat venepuncture. Presence of clinical laboratory test values judged clinically significant by the investigator. Positive test results for hepatitis B surface antigen (HBsAg), hepatitis C virus antibodies (HCVAb) or human immunodeficiency virus (HIV)-1 and/or -2 antibodies at screening. History or presence of drug abuse at screening or upon admission to the CRU. Participation in another clinical study with an experimental drug within 3 months before the first administration of the IMP. Any psychological, emotional problems, any disorders or resultant therapy that is likely to invalidate informed consent, or limit the ability of the subject to comply with the Clinical Study Protocol requirements.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: GRC 27864<br>Test Treatment GRC 27864 | Drug: GRC 27864<br> <br> |
| Active Comparator: Celecoxib<br>Active Comparator Treatment | Drug: Celecoxib<br> <br> |
| Placebo Comparator: Placebo<br>Placebo Treatment | Drug: Placebo<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Drug related adverse events (AEs) or any serious AEs | All treatment-emergent adverse events (TEAE) occurring in the study, in terms of nature, onset, duration, severity, relationship and outcome of adverse events and serious adverse events, in adult healthy volunteers from baseline to day 15. | 15 days after administration of the study drug | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time to Maximum Concentration (Tmax) of GRC 27864 |  | Pre-dose to and post-dose from 15 minutes to 72 hours | 
| Maximum Concentration (Cmax) of GRC 27864 |  | Post dose up to 72 hours | 
| Area Under Curve [(AUC (0-∞) and AUC (0-t)] of GRC 27864 |  | Pre-dose to and post-dose from 15 minutes to 72 hours |